W. Juvenal Tobin's Insider Trades & SAST Disclosures
W. Juvenal Tobin's most recent trade in Castle Biosciences Inc was a trade of 47,838 Restricted Stock Units done . Disclosure was reported to the exchange on March 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern W. Juvenal Tobin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 47,838 | 47,838 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 13,811 | 41,432 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2025 | 13,811 | 83,754 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.23 per share. | 04 Mar 2025 | 5,573 | 78,181 (0%) | 0% | 22.2 | 123,888 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 06 Jan 2025 | 2,230 | 69,943 (0%) | 0% | 30 | 66,900 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 15,961 | 70,139 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 15,961 | 31,922 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 6,169 | 6,170 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 6,169 | 73,676 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.91 per share. | 09 Dec 2024 | 3,887 | 66,252 (0%) | 0% | 30.9 | 120,147 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 1,750 | 68,002 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 1,750 | 0 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.63 per share. | 09 Dec 2024 | 1,503 | 72,173 (0%) | 0% | 29.6 | 44,534 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.63 per share. | 09 Dec 2024 | 495 | 67,507 (0%) | 0% | 29.6 | 14,667 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 05 Nov 2024 | 3,507 | 57,685 (0%) | 0% | 3.4 | 11,854 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2024 | 3,507 | 16,603 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 35.56 per share. | 05 Nov 2024 | 3,507 | 54,178 (0%) | 0% | 35.6 | 124,709 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 35.39 per share. | 01 Nov 2024 | 3,100 | 54,178 (0%) | 0% | 35.4 | 109,709 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 1,100 | 20,110 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 01 Nov 2024 | 1,100 | 57,278 (0%) | 0% | 3.4 | 3,718 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2024 | 10,641 | 10,641 | - | - | Performance-Based Stock Unit | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2024 | 10,641 | 58,770 (0%) | 0% | 0 | Common Stock | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.83 per share. | 09 Aug 2024 | 2,592 | 56,178 (0%) | 0% | 26.8 | 69,543 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 55,243 | 55,243 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Tobin Juvenal W. | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 3,400 | 21,210 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | W. Juvenal Tobin | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 02 Jan 2024 | 3,400 | 46,857 (0%) | 0% | 3.4 | 11,492 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 02 Jan 2024 | 3,301 | 43,457 (0%) | 0% | 2.4 | 7,889 | Common Stock |
| Castle Biosciences Inc | Juvenal W. Tobin | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2024 | 3,301 | 0 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Juvenal Tobin W. | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 15,961 | 47,883 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Juvenal W. Tobin | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 15,961 | 38,053 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | W. Tobin Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 6,170 | 40,336 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Juvenal W. Tobin | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 6,170 | 12,339 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | W. Juvenal Tobin | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.17 per share. | 09 Dec 2023 | 3,887 | 34,166 (0%) | 0% | 20.2 | 78,401 | Common Stock |
| Castle Biosciences Inc | W. Tobin Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 1,750 | 40,583 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | W. Tobin Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2023 | 1,750 | 1,750 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Juvenal W. Tobin | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.17 per share. | 09 Dec 2023 | 1,503 | 38,833 (0%) | 0% | 20.2 | 30,316 | Common Stock |
| Castle Biosciences Inc | Juvenal W. Tobin | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.17 per share. | 09 Dec 2023 | 427 | 40,156 (0%) | 0% | 20.2 | 8,613 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 01 Mar 2023 | 6,173 | 22,092 (0%) | 0% | 2.4 | 14,753 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2023 | 6,173 | 3,301 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 10 Nov 2022 | 3,221 | 9,049 (0%) | 0% | 2.4 | 7,698 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2022 | 3,221 | 9,474 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2022 | 479 | 0 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.36 per share. | 10 Nov 2022 | 479 | 5,828 (0%) | 0% | 2.4 | 1,130 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 2,230 | 2,230 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2021 | 42,550 | 42,550 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2021 | 24,679 | 24,679 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 1,750 | 5,250 | - | - | Restricted Stock Units | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2021 | 1,750 | 5,282 (0%) | 0% | - | Common Stock | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.52 per share. | 10 Dec 2021 | 427 | 4,855 (0%) | 0% | 40.5 | 17,302 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 75.40 per share. | 17 Jun 2021 | 10,000 | 2,827 (0%) | 0% | 75.4 | 754,000 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 5,263 | 479 | - | - | Stock option (right to buy) | |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.36 per share. | 17 Jun 2021 | 5,263 | 8,090 (0%) | 0% | 2.4 | 12,421 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 17 Jun 2021 | 4,737 | 12,827 (0%) | 0% | 2.4 | 11,321 | Common Stock |
| Castle Biosciences Inc | Tobin W. Juvenal | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2021 | 4,737 | 12,695 | - | - | Stock option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges